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Erythromycin A (I), erythromycin A 9-oxime (11), 9(S)-erythro-
mycylamine (V), and several new derivatives of these compounds, 
were assayed for their ability to inhibit the poly(A)-directed syn-
thesis of polylysine and the poly(C)-directed synthesis of polypro-
line in cell-free systems from Escherichia coli. The rate of poly-
peptide synthesis was inhibited 500/o by concentrations between 
0.5 and 1.5 ~tmol · dm-3 of the eight examined compounds, in the 
following decreasing order of activity : methylsuccinate of V (VI), 
I, V, II, methylsuccinate of II (111), p-toluenesulfonyl-V (VII), p-
-acetylamino-benzenesulfonyl-V (VIII), and ethylsuccinate of I 
(IV). The derivative of VII lacking cladinose (IX) showed lower 
but still significant activity. Hence, none of the substitutions in 
the position 9 of the macrolide ring, present in these compounds, 
impairs the ability of I to bind the prokaryotic ribosome and inhibit 
its function, which is the basis for antibacterial activity of ery-
thromycines. 
Erythromycin belongs to the macrolide group of antibiotics. Its anti-
bacterial activity is due to the specific inhibition of protein synthesis in 
prokaryotes (for reviews see Pestka1•2). The sensitivity to erythromycin is 
associated with the large ribosomal subunit3,4. Prokaryotic 70 S, but not 
eukaryotic 80 S ribosomes can strongly and specifically bind one molecule 
of the drug5• The specific binding site was traced to the isolated protein L 15 
of the large ribosomal subunit, though the absolute requirement for an 
additional protein, L 16, was demonstrated in the reconstituted 50 S subunit6. 
Using radioactive erythromycin, the association constant of 7.2 · 107 dm3 • mol-1 
was determined for erythromycin : 70 S ribosome complex'. Pestka and his 
co-workers have subsequently assayed an impressive number of erythromycin 
derivatives (over fifty) for their ability to inhibit the binding of radioactive 
erythromycin to ribosomes1•7, providing thus very accurate data about their 
activity. A good correlation was found between ribosomal binding of a 
derivative and its antibacterial activity8• 
* Taken in part from the M. Sc. theses submitted by P. M. and N. F. to Zagreb 
University 
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II R1, Ri=•N-OH, R3:cladinosyl, R4:-H 
nt Rt. R2::. =N-O-CO-!CH2~-COOCH3, Rl=cladinosyl, R4=-H 
IV Ri. Ri = =0, R3 :cladinosyl, R4:-CO-ICH2~COOCiHs 
V R1 = -NH2, R2:-H, R3:cladinosyl, Ri.= -H 
VI R1= -NH-CO-(CH2l2-COOCH3, Ri=-H, R3:cladinosyl, R4:-H 
Vil R1 =-NH-SO:!-@- CH3, Ri=-H, R3:cladinosyl, R4=-H 
VIII R1= -NH-SO:!-@- NH-CO-CH3, R2=-H, R3:cladinosyl, R4:-H 
IX R1 = -NH-s~-@- CH3 , R2:-H, RJ:-H, R,:-H 
The availability of several new compounds of the erythromydn series 
(Chart 1), including N-(substituted-benzenesulfonyl) erythromycylamines9, all 
displaY'ing high antibacterial activity, prompted our investigation of their 
activity at the very site of the erythromycin action, i.e. on the prokaryotic 
ribosome. Information about this activity seemed particularly important for 
erythromycin derivatives which could be considered, at the same time, as 
derivatives of benzenesulfonylamine, and potentially capable of an additional 
or different biological activity. However, lacking radioactive erythromycin, 
we had to perform measurements of the inhibition of polymerization of amino 
acids in the Escherichia coli cell-free system. A kinetic approach to such a 
study has been recently developed10• 
MATERIALS AND METHODS 
Escherichia coli MRE600 was grown to late exponential phase as described 
earlier11 • The cells were broken, and pre-incubated 30 000 g supernatant prepared 
by the usual procedures1o.i 1• All detailes of the cell-free polypeptide synthesis were 
recently described10, except for the synthesis of polyproline. Here, the concentration 
of poly(C) was 0.16 mg· cm-3, and [14C]-L-proline (specific radioactivity 120 Ci· mol-1) 
was used at 20 µmol · dm-3 ; Mg2• concentration was raised to 14 mmol · dm-3, and 
the reaction was terminated by the addition of 20°/o trichloroacetic acid. All reaction 
times were 10 min. Though the rate of polymerization was not strictly linear after 
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the first five minutes, higher ammounts of the polypeptide product, accumulated 
in longer reactions, enabled more accurate measurements. 
The synthesis of new erythromycin derivatives has been described previously9• 
RESULTS 
We have studied the inihibitory effect of several derivatives of I in two 
cell-free systems: synthesis of polylysine, directed by poly(A), and synthesis 
of polyproline, directed by poly(C). The reaction conditions were chosen as to 
measure reaction rates, rather than final levels of polymerazition10• Under 
such conditions, I was found, at least formally, to be a competitive inhibitor 
with respect to the synthetic polynucleotide, which, in turn, stimulated the 
polypeptide synthesis in a non~linear, pseudo-cooperative manner10• Since 
we were unable to reconcile the first effect with the known mechanism of 
the action of I, and could not find a plausible explanation for the cooperative 
effect, we did not attempt to run detailed kinetic experiments with all deri-
vatives we examined in the present research. Instead, the rate of polyme-
rization of amino acids was measured as a function of the inhibitor concen-
tration. Determining the 50<l/o-inhibitory concentrations was sufficient for 
comparison of the activity of individual derivatives. 
Dependence of the rate of polylysine synthesis on the inhibitor concen-
tration, i, is shown in Figure 1. Rates of synthesis in the presence of inhibitor, 
V;, are expressed as fractions of the rate in the un-inhibited control, v, which 
varied in individual experiments with various samples of cell-free extracts, 
from 0.15 to 0.22 nmol · cm-3 • min-1• Corresponding »blank« values, obtained 
in samples with no poly(A) added, were subtracted from each point; they 
amounted to less than 100/o of total incorporation. In this way, only the 
effect of inhibitors on the synthes s directed by poly(A) was measured. 
Similar experiments were performed in the cell-free system synthesizing 
polyprolipe under the direction of poly(C). The rate of polymerization without 
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Figure 1. Inhibition of polylysine synthesis by several derivatives of erythromycin. t, concentrat-
ion of inhibitor; v, reaction rate in un-inhibited control ; v i. reaction rate in the presence of 
inhibitor. Structures I to IX are shown in Chart I . 
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shown in Figure 2. Though the synthesis of polyproline is somewhat more 
resistant to I and its derivatives than the synthesis of polylysine, relative 
efficiencies of individual derivatives agree very well in the two systems. We 
have also assayed our compounds for the inhibition of polyphenylalanine 
synthesis directed by poly(U). Poor inhibition was ob1.::iined in all cases, in 
agreement with earlier f indings for the parent compound (1) 12 ; hence, no 
meaningful comparison of derivatives could be performed in this system. 
a~~~~~~~~~~~~"-~~~"-~~~"-~~__, 
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Figure 2. I nhibition of polyproline synthesis by several derivatives of erythromycin. For 
symbols see Figure 1. 
Numerous experiments with each derivative in the other two systems, 
i. e. poly(A) and poly(C)-directed polymerizations, are summarized in Table I. 
Among the compounds examined, one (VI) was found more efficient than 
I, several were 50 to 90-0/o as active as I (II, III, V, VII and VIII), while only 
the derivative lacking cladinose (IX) was considerably less active. 
TABLE I 
Relative Efficiency of Some Erythromycin Derivatives as Inhibitors of Polypeptide 
Synthesis 
Compound I II Ill IV v VI VII VIII IX 
Synthesis of polylysine 1.0 0.9 0.7 0.5 0.9 1.3 0.6 0.5 0.1 
Synthesis of polyproline 1.0 0.7 1.1 0.6 0.6 0.2 
The table summarizes results of experiments performed at various times, using different 
batches of cell-free extracts, polynucleotides, tRNA, etc. Relative efficiencies were obtained 
by dividing iso for I by i so for each of its derivatives, obtained in the same experiment. Relative 
efficiencies, obtained in such a way, never varied by more than 0.1, though the actual values 
for iso were occasionally less reproducible . 
DISCUSSION 
Erythromycin derivatives, assayed here for their ability to inhibit poly-
peptide synthesis in vitro, were previously found to posses substantial antimi-
crobial activity against a variety of standard bacterial strains and clinical 
isolates, which in some cases exceed the activity of the parent compound9• 
In spite of their importance for possible application, these data do not allow 
direct conclusions about structural requirements for the activity of I and 
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its derivatives on the bacterial target organelle, i. e. the ribosome. Permea-
bility of bacterial membranes for individual compounds, as well as possible 
metabolic degradati'on or modification, can in fact determine the apparent 
activity. This is undoubtely true for I itself, which is inactive against intact 
Gram-negative bacteria, but active in cell-free extracts derived from them. 
Such a drawback does not exist when the interaction of radioactive I with 
purified ribosomes is studied in vitro. Hence, the competition of erythromycin 
derivatives with radioactive I was used to asses the importance of functional .. 
groups of I for its activity1,1. 
We have good reason to believe that our approach, in which we measure 
the inhibition of amino acid polymerization, gives equally meaningfull results. 
In a cell-free system, the permeability barrier does not exist, and the incubatkm 
time of several minutes is too short to allow appreciable metabolic modifi-
cation. Nevertheless, there is an apparent discrepancy between our results 
and those obtained by the ribosome-binding method, when compounds tested 
by both methods (I, II and V) are compared. However, using reported asS'o-
ciation constants for these derivatives7,13, one can calculate that, at the ribo-
some concentration we used (ca. 10-6 mol · dm-3) , the fraction of ribosomes 
not in complex with the inhibitors at their 500/o-inhibitory concentrations, is 
close to one-half. Hence, the two methods are in good agreement, though 
the binding experiments are more sensitive. 
Our data for new derivatives of I demonstrate that new substitutions 
in position 9 of the macrolide ring, both in oxime ·and amine, do not impair 
the activity of the drug. The substituents can vary from simple alkyles or 
aryles (cf. ref. 1) to methylsuccionyl (III, VI) and p-substituted benzenesulfonyl 
(VII, VIII). On the other hand, the same substitutions improve some other 
'Properties of the drug, e. g. acid stability, and more significantly, high level 
in serum for many hours after oral administration9 • Esterification of the -OH 
group in the desosamine part of the molecule with ethylsuccinic acid leads 
to the very active compound IV; previous substitutions in the same position1 
resulted in somewhat decreased activity. The derivative of VII lack1ng cla-
dinose (IX) shows lower, but significant activity. Some activity of I lacking 
cladinose has been previously reported1, and it seems that substitutions in 
position 9, like in IX, at least cause no further inactivation, and possibly 
compensate for some loss of activity. 
In conclusion, our experiments add several new compounds to the list 
of erythromycin derivatives with strong inhibitory activity on bacterial ribo-
some. Though the substitutions in compounds II to VIII do not improve the 
activity to any significant degree, they add some other favourable properties 
to the drug9 • Therefore, these compounds may be of considerable practical 
interest. 
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SAZETAK 
Eritromicinska serija. X. Inhibitorska aktivnost nekoliko novih derivata eritromicina 
u polimerizacijskim sistemima bez stanica · 
P. Matijasevi.C, N . Franjic, s. Dokic i 2. Kucan 
lspitana je sposobnost eritromicina A (I) , eritromicin-A-9-oksima (II), 9(8)-eri-
tromicilamina (V), te nekih derivata tih spojeva da inhibiraju sintezu polilizina 
upravljanu poliadenilnom kiselinom i sintezu poliprolina upravljanu policitidilnom 
kiselinom, u sistemu bez stanica iz bakterije Escherichia coli. Osam ispitanih spojeva 
inhibiralo je brzinu sinteze polipeptida 500/o kod koncentracija izmedu 0,5 i 1,5 
µmol · dm-3, dajuci ovaj redoslijed aktivnosti: metilsukcinat-V (VI), I, V, II, metil-
sukcinat-11 (Ill), p-toluensulfonil-V (VII), p-acetilamino-benzensulfonil-V (VIII) , 
etilsukcinat-1 (IV). Derivat spoja VII bez kladinoze (IX) pokazao je manju, ali ipak 
znaeajnu aktivnost. Prema tome, nijedna supstitucija u polofaju 9 makrolidnog 
prstena u proucenim spojevima ne ponistava sposobnost spoja I da se veze na pro-
kariotski ribosom i inhibira njegovu funkciju, sto cini osnovu antimikrobne aktiv-
nosti eritromicina. 
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